Alphabet's Google is working on a new initiative to make its artificial intelligence chips better at running PyTorch, the ...

Danielle Gansky was 7 years old when an administrator at her upscale private girls’ school in suburban Philadelphia flagged problems with her academic performance. She was a bubbly and creative kid, ...

Artur is a copywriter and SEO specialist, as well as a small business owner. In his free time, he loves to play computer games and is glad that he was able to connect his professional career with his ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A pill designed to further lower ...

Novo Nordisk (NVO) has received approval to market its oral GLP-1 medicine Rybelsus in the U.S. to reduce the risk of major cardiovascular events such as stroke in adults with type 2 diabetes, the ...

WASHINGTON (AP) — Federal officials have approved another generic version of the abortion pill mifepristone, a regulatory formality that quickly triggered pushback from anti-abortion groups and ...

Novo Nordisk (NVO) said Wednesday that oral semaglutide 25 mg (Wegovy in a pill) delivered 16.6% weight loss in people with obesity in a phase 3 trial. In the 64-week OASIS 4 study of 307 adults ...

Borderlands 4 is out now! Yay, that’s exciting. However, on PC, it has some performance problems that might dampen your enjoyment. But hey, whatever, you’re here because you want to figure out how ...

About two years after the US Food and Drug Administration approved the first over-the-counter birth control pill in the United States, a new study suggests that many people who may not have had access ...

Share on Pinterest GLP-1 drugmaker Eli Lilly’s new weight loss pill orforglipron showed meaningful weight loss results in a recent clinical trial. Scott Olson/Getty Images Eli Lilly’s new oral GLP-1 ...

In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year. By Gina Kolata People who were overweight or had obesity lost a ...